Olmefast
Generic Name
Olmesartan Medoxomil
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmefast 10 mg tablet | ৳ 5.00 | ৳ 50.00 |
| olmefast 20 mg tablet | ৳ 8.00 | ৳ 80.00 |
| olmefast 40 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Olmefast (Olmesartan Medoxomil) is an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension) in adults and children 6 years and older. It helps to lower blood pressure, which can prevent strokes, heart attacks, and kidney problems.
Uses & Indications
Dosage
Adults
Initial dose: 20 mg once daily. May be increased to 40 mg once daily after 2 weeks if blood pressure is not adequately controlled.
Elderly
No initial dose adjustment is generally required, but close monitoring is recommended.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance < 40 mL/min), a starting dose of 10 mg once daily is recommended, with careful titration.
How to Take
Olmefast can be taken orally, with or without food. It should be taken at the same time each day.
Mechanism of Action
Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor, primarily located in vascular smooth muscle. This blockade inhibits the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation, reduced peripheral resistance, and decreased blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect seen within 2 weeks, maximal effect usually achieved after 8 weeks of therapy.
Excretion
Excreted primarily via the liver (biliary excretion, approximately 50-60%) and kidneys (approximately 35-40%).
Half life
Approximately 13 hours.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract following oral administration; bioavailability is approximately 26%. Peak plasma concentrations are reached in 1-2 hours.
Metabolism
Olmesartan medoxomil is a prodrug that is rapidly and completely hydrolyzed to olmesartan during absorption from the gastrointestinal tract. There is virtually no further metabolism of olmesartan.
Side Effects
Contraindications
- •Pregnancy (second and third trimesters).
- •Bilateral renal artery stenosis.
- •Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- •Concomitant use with aliskiren in patients with diabetes or renal impairment.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity.
Other Antihypertensives
Additive hypotensive effects.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect and increase the risk of renal impairment.
Potassium-Sparing Diuretics/Potassium Supplements
Increased risk of hyperkalemia.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and possibly tachycardia or bradycardia. Treatment is supportive; if ingestion is recent, gastric lavage may be considered. Closely monitor vital signs and renal function.
Pregnancy & Lactation
Pregnancy: Contraindicated during the second and third trimesters due to fetal toxicity. Discontinue immediately if pregnancy is detected. Lactation: Not recommended during breastfeeding due to potential risk to the nursing infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Available in pharmacies and hospitals
Approval Status
Approved by FDA/DGDA
Patent Status
Patent Expired
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
